UNSPSC 51283602: Rifamycin

This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DU69T8ZZPA. European Medicines Agency schedules Rifamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Rifamycin generally arises in the molecular formula C37H47NO12.

UNSPSC 51283602 Rifamycin is a Commodity code that nominally denotes a specific antibiotic drug; however, the recent state and local procurement activity associated with this code shows little direct alignment with rifamycin procurement itself. Instead, the opportunities tagged under this code span a broader range of pharmaceutical and medical supply procurements, including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, generic pharmaceuticals and OTC products, and first aid supplies for emergency response. State and local issuing bodies acquiring under this code include county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. The scope of work reflects acquisitions of emergency medical consumables, pharmacy benefit administration services, and standardized generic drug inventory supporting public health initiatives and emergency response operations.

Recent activity appears concentrated in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a significant cooperative vehicle for multi-state procurement. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, requiring vendor relationships with authorized wholesalers and a 3 percent administrative fee. The mismatch between the rifamycin commodity code and the actual procurement activity suggests the code classification may reflect a data-entry error or overly broad tagging by issuing bodies.